Compare RLYB & UG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RLYB | UG |
|---|---|---|
| Founded | 2018 | 1942 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Package Goods/Cosmetics |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.7M | 30.2M |
| IPO Year | 2021 | 1995 |
| Metric | RLYB | UG |
|---|---|---|
| Price | $8.67 | $6.25 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 263.8K | 2.8K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 7.99% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.20 |
| Revenue | $858,000.00 | ★ $12,181,971.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $32.40 |
| Revenue Growth | ★ 43.00 | 11.91 |
| 52 Week Low | $0.22 | $5.58 |
| 52 Week High | $11.49 | $9.88 |
| Indicator | RLYB | UG |
|---|---|---|
| Relative Strength Index (RSI) | 57.69 | 40.87 |
| Support Level | $0.48 | $5.58 |
| Resistance Level | $11.49 | $6.78 |
| Average True Range (ATR) | 0.69 | 0.13 |
| MACD | -0.41 | -0.03 |
| Stochastic Oscillator | 0.38 | 21.92 |
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
United-Guardian Inc manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and specialty industrial products. Its product portfolio includes Klensoft, Deselex, Renacidin, Lubrajel Fluid. The company's pharmaceutical products are sold to and distributed by full-line drug wholesalers throughout the United States. Its medical and specialty industrial products are sold directly by the company to the end-users of those products or, in some cases, to contract manufacturers used by some of those end users. It operates in one business segment and its current product lines are separated into four distinct product categories that are cosmetic ingredients, pharmaceuticals, medical lubricants and sexual wellness. It derives key revenue from the sales made in the U.S.